Actos Ups The Chances of Bladder Cancer And Has Therefore Spawned Many Lawsuits

by Terry Bryant

Many patients who have taken pioglitazone and been diagnosed with bladder cancer have felt they have no other recourse than to file an Actos law suit. Independent studies by the FDA and health organizations in other countries have confirmed that there is a linkage between this drug and bladder cancer, in addition to other Actos side effects. In fact, France and Germany consider it too dangerous to use on patients, and have either suspended or banned its use.

According to the FDA, patients who have taken pioglitazone for 12 months or longer have a 40 percent increased risk of developing bladder cancer. This was confirmed in an ongoing 10-year study by the administration and in a French study tracking 1.5 million patients. Between January and October 2010, 2.3 million people were prescribed the drug. Many of these people may consider filing an Actos law suit once the cancer presents itself. Takeda, the medication’s manufacturer, was unaware of these risks when it released the drug for commercial use. It has slowly admitted to the presence of other Actos side effects, like a greater rate of fractures of the arm, hands and feet.

While urine in the blood is the most common symptom of  a bladder problem, this can be hard to detect. The blood may or may not be able to be seen by the patient, so only a doctor can confirm its presence. Frequent urination, pain while urinating and an inability to urinate are also signs that cancer may be present. Anyone who has been diagnosed with bladder cancer and has taken pioglitazone should consider consulting with a lawyer about filing an Actos law suit as the treatment will be lengthy and expensive.